Obesity drugs won't be covered by Medicare under 2026 CMS policy [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
coverage for anti-obesity drugs such as Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide). First introduced in November 2024, the proposed rule sought to allow Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonists (GLP-1RAs) when prescribed alone, not just for type 2 diabetes. The Biden administration estimated the change could have extended coverage to an additional 3.4 million adults. According to the National Institutes of Health (NIH), approximately 42% of US adults are classified as obese. Under its current policy, Medicare only covers GLP-1RA drugs such as Novo Nordisk's Ozempic (semaglutide) and Eli Lilly's Mounjaro (tirzepatide) when prescribed for diabetes, not for weight loss. While some states opt to cover weight-loss medications through Medicaid, the majority do not. The Trump administration's finalised 2026 Medicare Advantage and Part D policies did not include the proposed changes related to weight-loss drug coverage,
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Lawsuits alleging GLP-1 drugs led to blindness to be centralized [Seeking Alpha]Seeking Alpha
- Update: Market Chatter: Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026 [Yahoo! Finance]Yahoo! Finance
- 2 Predictions for Novo Nordisk in 2026 [Yahoo! Finance]Yahoo! Finance
- Eli Lilly: The Right Long-Term Strategy [Seeking Alpha]Seeking Alpha
- Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website